These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21235439)

  • 1. Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs.
    Cox CD; Garbaccio RM
    Anticancer Agents Med Chem; 2010 Nov; 10(9):697-712. PubMed ID: 21235439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer.
    Cox CD; Coleman PJ; Breslin MJ; Whitman DB; Garbaccio RM; Fraley ME; Buser CA; Walsh ES; Hamilton K; Schaber MD; Lobell RB; Tao W; Davide JP; Diehl RE; Abrams MT; South VJ; Huber HE; Torrent M; Prueksaritanont T; Li C; Slaughter DE; Mahan E; Fernandez-Metzler C; Yan Y; Kuo LC; Kohl NE; Hartman GD
    J Med Chem; 2008 Jul; 51(14):4239-52. PubMed ID: 18578472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel spiro 1,3,4-thiadiazolines as potent, orally bioavailable and brain penetrant KSP inhibitors.
    Mansoor UF; Angeles AR; Dai C; Yang L; Vitharana D; Basso AD; Gray K; Tang H; Liu M; Liang L; Allbritton O; Siddiqui MA
    Bioorg Med Chem; 2015 May; 23(10):2424-34. PubMed ID: 25868746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress on kinesin spindle protein inhibitors as anti-cancer agents.
    Zhang Y; Xu W
    Anticancer Agents Med Chem; 2008 Aug; 8(6):698-704. PubMed ID: 18690830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of a kinesin inhibitor.
    Sakowicz R; Finer JT; Beraud C; Crompton A; Lewis E; Fritsch A; Lee Y; Mak J; Moody R; Turincio R; Chabala JC; Gonzales P; Roth S; Weitman S; Wood KW
    Cancer Res; 2004 May; 64(9):3276-80. PubMed ID: 15126370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KSP inhibitors as antimitotic agents.
    Pérez-Melero C
    Curr Top Med Chem; 2014; 14(20):2286-311. PubMed ID: 25434354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP.
    Fraley ME; Garbaccio RM; Arrington KL; Hoffman WF; Tasber ES; Coleman PJ; Buser CA; Walsh ES; Hamilton K; Fernandes C; Schaber MD; Lobell RB; Tao W; South VJ; Yan Y; Kuo LC; Prueksaritanont T; Shu C; Torrent M; Heimbrook DC; Kohl NE; Huber HE; Hartman GD
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1775-9. PubMed ID: 16439123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformation-dependent ligand regulation of ATP hydrolysis by human KSP: activation of basal hydrolysis and inhibition of microtubule-stimulated hydrolysis by a single, small molecule modulator.
    Luo L; Carson JD; Molnar KS; Tuske SJ; Coales SJ; Hamuro Y; Sung CM; Sudakin V; Auger KR; Dhanak D; Jackson JR; Huang PS; Tummino PJ; Copeland RA
    J Am Chem Soc; 2008 Jun; 130(24):7584-91. PubMed ID: 18491908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage.
    Tao W; South VJ; Zhang Y; Davide JP; Farrell L; Kohl NE; Sepp-Lorenzino L; Lobell RB
    Cancer Cell; 2005 Jul; 8(1):49-59. PubMed ID: 16023598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developments of kinesin spindle protein inhibitors as antitumor agents based on the five-membered heterocycle scaffolds.
    Zhao GD; Wan RZ; Liu ZP
    Curr Med Chem; 2014; 21(23):2691-701. PubMed ID: 24606497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of tetrahydro-beta-carbolines as inhibitors of the mitotic kinesin KSP.
    Liu F; Yu LQ; Jiang C; Yang L; Wu WT; You QD
    Bioorg Med Chem; 2010 Jun; 18(12):4167-77. PubMed ID: 20537544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents.
    Balakumar C; Ramesh M; Tham CL; Khathi SP; Kozielski F; Srinivasulu C; Hampannavar GA; Sayyad N; Soliman ME; Karpoormath R
    J Biomol Struct Dyn; 2018 Nov; 36(14):3687-3704. PubMed ID: 29064326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinesin spindle protein (KSP) inhibitors in combination with chemotherapeutic agents for cancer therapy.
    Song H; Zhou S; Wang R; Li S
    ChemMedChem; 2013 Nov; 8(11):1736-49. PubMed ID: 23964020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of KSP Inhibitors as Anti-cancer Therapeutics: An Update.
    Chamariya R; Suvarna V
    Anticancer Agents Med Chem; 2022; 22(14):2517-2538. PubMed ID: 35043768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinesin spindle protein inhibitors in cancer: a patent review (2008 - present).
    Jiang C; You Q
    Expert Opin Ther Pat; 2013 Dec; 23(12):1547-60. PubMed ID: 23978071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by beta-fluorination to overcome cellular efflux by P-glycoprotein.
    Cox CD; Breslin MJ; Whitman DB; Coleman PJ; Garbaccio RM; Fraley ME; Zrada MM; Buser CA; Walsh ES; Hamilton K; Lobell RB; Tao W; Abrams MT; South VJ; Huber HE; Kohl NE; Hartman GD
    Bioorg Med Chem Lett; 2007 May; 17(10):2697-702. PubMed ID: 17395460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent progress in the identification and clinical evaluation of inhibitors of the mitotic kinesin KSP.
    Knight SD; Parrish CA
    Curr Top Med Chem; 2008; 8(10):888-904. PubMed ID: 18673173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP.
    Cox CD; Breslin MJ; Mariano BJ; Coleman PJ; Buser CA; Walsh ES; Hamilton K; Huber HE; Kohl NE; Torrent M; Yan Y; Kuo LC; Hartman GD
    Bioorg Med Chem Lett; 2005 Apr; 15(8):2041-5. PubMed ID: 15808464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class.
    Lerchen HG; Wittrock S; Stelte-Ludwig B; Sommer A; Berndt S; Griebenow N; Rebstock AS; Johannes S; Cancho-Grande Y; Mahlert C; Greven S; Terjung C
    Angew Chem Int Ed Engl; 2018 Nov; 57(46):15243-15247. PubMed ID: 30180286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the kinesin spindle protein: basic principles and clinical implications.
    Sarli V; Giannis A
    Clin Cancer Res; 2008 Dec; 14(23):7583-7. PubMed ID: 19047082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.